Veradigm Completes Strategic Alternatives Review and Launches Operational Assessment
Veradigm Completes Strategic Alternatives Review and Announces Operational Assessment Veradigm® (OTCMKTS: MDRX), a prominent provider of healthcare data and technology solutions, has concluded its previously announced strategic alternatives review, aimed at maximizing stockholder value. The company’s Board of Directors (the…
TROPION-Lung12 Phase 3 Trial Launches to Assess DATROWAY® in Early-Stage NSCLC Patients at High Relapse Risk
TROPION-Lung12 Phase 3 Trial Begins to Evaluate DATROWAY® as Part of Adjuvant Treatment for High-Risk Early-Stage Non-Small Cell Lung Cancer Patients Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all…
Enveric Biosciences Receives Patent Approval for Lead Drug Candidate EB-003 from USPTO
Enveric Biosciences Announces Notice of Allowance for Patent on Lead Drug Candidate EB-003 Enveric Biosciences, a biotechnology firm focused on pioneering neuroplastogenic small-molecule therapeutics for mental health disorders, announced today that it has received a Notice of Allowance (NOA) from…
Science Exchange Unveils New Clinical Development Solution
Science Exchange Launches Clinical Development Solution to Revolutionize Clinical Trial Management Science Exchange, a leader in supplier orchestration solutions for the life sciences industry, has unveiled its new Clinical Development Solution. This platform aims to streamline and enhance the management…
Mirvie RNA Platform Identifies Unique Molecular Signal for Babies at Risk of Severe Growth Restriction
Mirvie, a leader in personalized and preventive care for pregnancy complications, recently presented groundbreaking findings at the Society for Maternal-Fetal Medicine annual meeting. The company revealed that its innovative RNA platform has identified a unique molecular signature that can predict…
Henry Schein Announces KKR Investment, Board Changes, and Preliminary 2025 Financial Outlook
Henry Schein Announces Strategic Investment by KKR, Board Changes, and Provides Financial Results and 2025 Guidance Henry Schein, Inc. (Nasdaq: HSIC), the world’s leading provider of health care solutions for office-based dental and medical professionals, today announced a strategic investment…
Cardinal Health Reports Q2 FY25 Results, Raises Outlook
Cardinal Health Reports Q2 FY25 Results, Raises Outlook Cardinal Health Reports Strong Q2 FY25 Results and Strategic Growth Moves Revenue and Earnings Overview Cardinal Health (NYSE: CAH) has reported a revenue of $55.3 billion for the second quarter of fiscal…
Aetna Better Health of Illinois Adds New Benefits to Tackle Health Disparities
Aetna Better Health of Illinois, a CVS Health company (NYSE: CVS), has introduced three new lifestyle benefits designed to support its Medicaid members enrolled through the HealthChoice Illinois program. These benefits aim to reduce barriers to a healthier lifestyle by…
Cigna Group Announces Q4 & Full-Year 2024 Results, Sets 2025 Outlook, and Raises Dividend
Cigna Group Reports Strong 2024 Financial Results, Sets 2025 Outlook, and Announces Dividend Increase Global health company The Cigna Group (NYSE: CI) has released its financial results for the fourth quarter and full year 2024, demonstrating continued strength in Evernorth…
Hawthorne Health and RxE2 Collaborate to Enhance Patient Access in Clinical Trials
Hawthorne Health and RxE2 Partner to Transform Community-Based Clinical Trial Delivery Hawthorne Health, a leader in community-based clinical trial delivery, and RxE2, a pioneer in pharmacist-led clinical trial services, have announced a groundbreaking strategic partnership aimed at revolutionizing the way…
Quanta System Marks 40 Years of Innovation and Unveils Exclusive New Partnership at IMCAS 2025
Quanta System, a leader in medical laser technology, is celebrating a significant milestone in 2025: its 40th anniversary. This momentous occasion not only honors the company’s rich history of technological advancements and breakthroughs but also marks the start of an…
Kyowa Kirin and Swixx BioPharma Expand POTELIGEO® Access for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe
Kyowa Kirin and Swixx BioPharma Expand Access to POTELIGEO® for Mycosis Fungoides and Sézary Syndrome in Central and Eastern Europe Kyowa Kirin International (KKI), a fully owned subsidiary of Kyowa Kirin Co. Ltd., in partnership with Swixx BioPharma AG, recently…